Form 4: Avalo Therapeutics Director Samantha Truex Acquires Shares Through RSU Vesting

Director Samantha Truex acquired 3,167 shares of Avalo Therapeutics common stock through the vesting of restricted stock units on March 28, 2025.

Summary

• On March 28, 2025, Samantha Truex, a director of Avalo Therapeutics, acquired 3,167 shares of common stock.
• This acquisition resulted from the vesting of restricted stock units (RSUs).
• These RSUs convert into common stock on a one-for-one basis.
• Truex was initially granted 9,500 RSUs on August 13, 2024, which vest in three equal installments on March 28, 2025, March 28, 2026, and March 28, 2027, contingent upon continued service.
• Following this transaction, Truex directly owns 6,333 shares of Avalo Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard insider transaction related to equity compensation. It doesn't indicate any strategic shift or significant event.

Positives

• The vesting of RSUs indicates continued service and commitment of a director to the company.
• Director Truex now directly owns 6,333 shares of Avalo Therapeutics common stock.

Future Outlook

The remaining RSUs will vest on March 28, 2026, and March 28, 2027, subject to continued service.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency to investors about the trading activities of company directors and officers. This particular filing reflects the standard vesting schedule of previously granted equity compensation.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The vesting of RSUs aligns the director's interests with those of the shareholders.

Key Dates

Keywords

Avalo Therapeutics, Samantha Truex, Director, Form 4, RSU, Restricted Stock Units, Beneficial Ownership, AVTX, Vesting